Jennison Associates LLC Sells 42,539 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Jennison Associates LLC sold 42,539 shares of Prestige Consumer Healthcare, cutting its stake by 16.9% to 209,677 shares (about 0.44% of the company, valued at ~$12.94M) during the fourth quarter.
• Prestige missed quarterly expectations, reporting $1.14 EPS vs. $1.16 expected and $283.44M revenue vs. $286.93M expected, and set FY2026 guidance at 4.54 EPS, which matches analysts' consensus; the stock carries a consensus "Hold" rating with an average target of $76.50.
• PBH opened at $54.98 and is trading near its 52‑week low ($51.24) versus a high of $89.37; the company has a market cap of ~$2.60B, a P/E of 14.55, and institutional investors own about 99.95% of the shares.

Jennison Associates LLC lowered its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 209,677 shares of the company's stock after selling 42,539 shares during the period. Jennison Associates LLC owned approximately 0.44% of Prestige Consumer Healthcare worth $12,935,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its holdings in shares of Prestige Consumer Healthcare by 4.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company's stock worth $161,723,000 after buying an additional 119,459 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company's stock worth $98,776,000 after buying an additional 21,085 shares during the period. Bank of America Corp DE increased its holdings in shares of Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company's stock worth $57,601,000 after buying an additional 115,459 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Prestige Consumer Healthcare by 10.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company's stock worth $40,147,000 after buying an additional 60,496 shares during the period. Finally, Raymond James Financial Inc. increased its holdings in shares of Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company's stock worth $39,807,000 after buying an additional 86,373 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.40% of the company's stock.

Prestige Consumer Healthcare Stock Down 2.4%

PBH stock opened at $54.98 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The business's 50 day moving average price is $61.10 and its two-hundred day moving average price is $62.06. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of 14.55, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to analysts' expectations of $286.93 million. During the same quarter last year, the company posted $1.22 EPS. The firm's revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PBH shares. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a report on Friday, January 30th. Weiss Ratings restated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $76.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.